Skip to content

Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large Prostate

Comparison of Pasmakinetic Enucleation of the Prostate With Bipolar Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hypertrophy Patients With Large Prostate

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01637701
Enrollment
80
Registered
2012-07-11
Start date
2004-06-30
Completion date
2011-12-31
Last updated
2012-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPH With Large Prostate

Keywords

benign prostatic hypertrophy, bipolar transurethral resection of the prostate, plasmakinetic enucleation of the prostate

Brief summary

The goal of this study is to compare the perioperative and postoperative characters of plasmakinetic enucleation of the prostate(PkEP) with bipolar TURP(B-TURP) for BPH patients with large prostate.

Detailed description

Despite the availability of numerous minimally invasive alternatives, monopolar transurethral resection of the prostate (TURP) remains the most frequently performed operation for benign prostatic hypertrophy (BPH) with small to moderate size prostates. Nevertheless, TURP for large prostates is associated with various complications and unsatisfactory long-term results. B-TURP and PkEP have both been proved to have more favorable postoperative outcomes than monopolar TURP. But whether B-TURP or PkEP is better remain controversial. We aim to compare the perioperative and postoperative characters of PkEP with B-TURP for BPH patients with large prostate. Moreover, we evaluate the long-term results of both approaches.

Interventions

PROCEDUREPkEP

Plasmakinetic enucleation of the prostate

PROCEDUREB-TURP

Bipolar transurethral resection of the prostate

Sponsors

Fuzhou General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
50 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Qmax \< 10 mL/s, IPSS \>19 * Age between 50 and 70 years * Prostate volume between 70 and 200 mL, as determined by TRUS, and medical therapy failure.

Exclusion criteria

* Patients with neurogenic bladder * Urethral stricture * Bladder tumor * Prostate cancer and previous prostate bladder neck * Urethral surgery * PSA\>4ng/ml, or receiving prostate biopsy within 3 months

Design outcomes

Primary

MeasureTime frameDescription
time of catheterizationAt the end of both procedures, a 22F three-way Folley catheter was inserted and continuous bladder irrigation was performed. Irrigation was discontinued when the catheter drainage became clear, and the catheter was removed 6 h later.Two experienced urologists who were unaware of the surgical modality used decided bladder irrigation and catheter removal for all cases.

Secondary

MeasureTime frame
resected adenoma weight as a measure of treatment efficacy
changes in serum haemoglobin as a measure of one of the complications
Operation time
postoperative Qmax as a masure of treatment efficacy and durability5 years
re-operation rate as a measure of durability5 years
postoperative International Prostate Symptom Score as a measure of treatment efficacy and durability5 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026